Key Drivers
- High leverage
- Weak profitability
- Positive EBITDA
AIAI Summary
Brookdale has moved from a distressed turnaround call to a leverage-driven execution bet—operational tailwinds and a $600M refinancing de-risk near-term survival, but this is only investible if quarterly free cash flow turns sustainably positive and the company either extends/refinances 2026–27 maturities without heavy equity dilution while keeping occupancy/RevPAR gains intact.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High leverage
- •Weak profitability
- •Positive EBITDA
BKD produces positive EBITDA and solid gross margins but is under solvency and liquidity pressure from heavy debt, negative equity and large noncash charges that drive FY net losses and weak returns.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Support holds
- •Resistance ahead
Stock is in a short-term downtrend with price meaningfully below last month's SMA (~$14.67), holding near-term support around $13.70–$13.90 but needing a decisive move above $15.10–$15.40 (and the SMA) to negate the bearish case — a break below $13.70 on heavy volume would increase downside risk.
~10–12% decline since late
Sentiment & News
Key News Insights:
- •Large institutional buys
- •Significant sell-off
- •Ongoing disclosures
Institutional investors rotated into Brookdale—large buys by Mason, Victory and Quantbot offset by AYAL's sizeable sale—while the company issued routine occupancy data and stepped up conference outreach.
Net positive investor repositioning and active investor engagement should support liquidity and visibility, potentially stabilizing the stock amid recent momentum-driven volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings